Cargando…

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy

Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT) associated with high morbidity and mortality. High-risk TA-TMA (hrTA-TMA) is characterized by multifactorial endothelial damage caused by environmental st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez-Ganda, Laura, Benitez-Carabante, Maria Isabel, Fernandez-Polo, Aurora, Muñoz-Lopez, Marina, Renedo-Miro, Berta, Ariceta, Gema, Diaz De Heredia, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632356/ https://www.ncbi.nlm.nih.gov/pubmed/34858907 http://dx.doi.org/10.3389/fped.2021.761726

Ejemplares similares

Home Albumin Infusion Therapy, Another Alternative Treatment in Patients With Congenital Nephrotic Syndrome of the Finnish Type
por: Serramontmany, Eugènia, et al.
Publicado: (2021)

Eculizumab in chemotherapy-induced thrombotic microangiopathy
por: Schulte-Kemna, Lena, et al.
Publicado: (2020)

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
por: Grall, Maximilien, et al.
Publicado: (2021)

The use of eculizumab in gemcitabine induced thrombotic microangiopathy
por: Krishnappa, Vinod, et al.
Publicado: (2018)

The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
por: Gabr, Jihad Ben, et al.
Publicado: (2020)

CMV hyperimmune globulin as salvage therapy for recurrent or refractory CMV infection in children undergoing hematopoietic stem cell transplantation
por: Panesso, Melissa, et al.
Publicado: (2023)

Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab
por: Jin, Anna, et al.
Publicado: (2016)

Scleroderma Renal Crisis With Thrombotic Microangiopathy Treated With Eculizumab
por: Saba, Ludovic, et al.
Publicado: (2022)

Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease
por: Chonat, Satheesh, et al.
Publicado: (2020)

Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease
por: Garcia-Ortega, Patricia, et al.
Publicado: (2022)

Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report
por: Facchini, Ludovica, et al.
Publicado: (2017)

Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding
por: Fujita, Yoko, et al.
Publicado: (2020)

Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab
por: Efe, Orhan, et al.
Publicado: (2021)

Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
por: Vitkauskaitė, Monika, et al.
Publicado: (2022)

Bevacizumab-Associated Thrombotic Microangiopathy Treated with Eculizumab: A Case Report
por: Padilha, Wallace Stwart Carvalho, et al.
Publicado: (2023)

Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report
por: Van den Eeckhaut, Lisa, et al.
Publicado: (2022)

Extra-Renal Manifestations of Complement-Mediated Thrombotic Microangiopathies
por: Hofer, Johannes, et al.
Publicado: (2014)

Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
por: Gosain, Rahul, et al.
Publicado: (2017)

The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report
por: Bjørkto, Magnus Holter, et al.
Publicado: (2021)

Linear Growth in Pediatric Kidney Transplant Population
por: Lopez-Gonzalez, Mercedes, et al.
Publicado: (2020)

Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management
por: Dvorak, Christopher C., et al.
Publicado: (2019)

Case report: Thrombotic microangiopathy in pediatric multisystem inflammatory syndrome associated with COVID-19: a case series
por: Nalçacıoğlu, Hülya, et al.
Publicado: (2023)

Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome
por: Thomas, Christie P., et al.
Publicado: (2015)

Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab
por: Uriarte, Maite Hurtado, et al.
Publicado: (2018)

Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer
por: Hausberg, Martin, et al.
Publicado: (2019)

A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
por: Wright, Rachael D., et al.
Publicado: (2020)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021)

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT
por: Mizuno, Kana, et al.
Publicado: (2022)

Serious Hemorrhagic Complications After Successful Treatment of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy With Defibrotide in Pediatric Patient With Myelodysplastic Syndrome
por: Laberko, Alexandra, et al.
Publicado: (2020)

The successful use of eculizumab for treatment of thrombotic microangiopathy in pediatric acute SARS-CoV2 infection and multisystem inflammatory syndrome in children
por: Aurora, Tarun, et al.
Publicado: (2022)

Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia
por: Wölfl, Matthias, et al.
Publicado: (2022)

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
por: Lanfranco, Luca, et al.
Publicado: (2017)

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
por: Allinovi, Marco, et al.
Publicado: (2017)

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2020)

Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report
por: Torres, Everardo Arias, et al.
Publicado: (2021)

Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy
por: Sridharan, Meera, et al.
Publicado: (2022)

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
por: Acosta-Medina, Aldo A., et al.
Publicado: (2022)

Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis
por: Zhang, Rui, et al.
Publicado: (2021)

Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report
por: Nakamura, Masahiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rk5c4prkupe2qals4l6umpv7qv